Steve Chesney analyst ATLANTIC EQUITIES

Currently out of the existing stock ratings of Steve Chesney, 23 are a BUY (45.1%), 26 are a HOLD (50.98%), 2 are a SELL (3.92%).

Steve Chesney

Work Performance Price Targets & Ratings Chart

Analyst Steve Chesney, currently employed at ATLANTIC EQUITIES, carries an average stock price target met ratio of 71.67% that have a potential upside of 31.05% achieved within 507 days.

Steve Chesney’s has documented 96 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BMY, Bristol-Myers Squibb Company at 06-Feb-2024.

Wall Street Analyst Steve Chesney

Analyst best performing recommendations are on CELG (CELGENE).
The best stock recommendation documented was for CELG (CELGENE) at 12/18/2015. The price target of $122 was fulfilled within 5 days with a profit of $11.86 (10.77%) receiving and performance score of 21.54.

Average potential price target upside

BIIB Biogen ABBV AbbVie AMGN Amgen BMY Bristol-Myers Squibb Company JNJ Johnson & Johnson MRK Merck mpany IDXX IDEXX Laboratories PFE Pfizer ZTS Zoetis CELG Celgene

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 28-Sep-2022

$241

$33.06 (15.90%)

$221

Hold Since 15-Jun-2021

$215

$7.06 (3.40%)

$200

Hold Since 13-Feb-2025

$231

$23.06 (11.09%)

$222

Buy Since 04-Mar-2022

$240

$32.06 (15.42%)

$242

Buy Since 24-Apr-2020

$248

$40.06 (19.27%)

$245

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Steve Chesney?

On 2015

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?